Allianz Asset Management
PBYI icon

Allianz Asset Management’s Puma Biotechnology PBYI Stock Holding History

Allianz Asset Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-4,392
Closed -$434K – 2713
2017
Q4 		$434K Buy
4,392
+1,049
+31% +$117K ﹤0.01% 2447
2017
Q3 		$400K Sell
3,343
-456
-12% -$42.4K ﹤0.01% 2468
2017
Q2 		$330K Buy
+3,799
New +$213K ﹤0.01% 2490
2015
Q2 		– Sell
-13,960
Closed -$3.3M – 2473
2015
Q1 		$3.3M Sell
13,960
-45,684
-77% -$9.77M ﹤0.01% 1372
2014
Q4 		$11.3M Sell
59,644
-49,387
-45% -$11M 0.01% 912
2014
Q3 		$26M Sell
109,031
-22,564
-17% -$4.63M 0.03% 544
2014
Q2 		$8.69M Buy
+131,595
New +$9.36M 0.01% 773

Other funds holding PBYI

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Allianz Asset Management's PBYI Position: Q1 2018 in Review

Allianz Asset Management sold out of Puma Biotechnology (PBYI) in Q1 2018, closing a stake of 4,392 shares — an estimated $434K sold.

Allianz Asset Management first reported a position in PBYI in Q2 2014 and held it in 7 quarters. The position peaked at $26M in Q3 2014. 178 funds tracked by Wall St. Rank hold PBYI as of Q1 2018.

  • Allianz Asset Management reported no remaining Puma Biotechnology position as of Q1 2018 after selling out during the quarter.
  • Allianz Asset Management sold 4,392 Puma Biotechnology shares in Q1 2018, an estimated $434K.
  • Allianz Asset Management first reported a position in Puma Biotechnology in Q2 2014 and held it in 7 quarters.
  • Allianz Asset Management's Puma Biotechnology position peaked at $26M in Q3 2014.
  • 178 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2018.

Based on Allianz Asset Management's 13F filing for Q1 2018, filed 14 May 2018.